Skip to content
HowShorted

INTERCEPT PHARMACEUTICALS, INC. short interest in 2022

In 2022, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 28.36% of shares outstanding on 14 Jan 2022 to 8.74% on 30 Dec 2022, a change of -19.62 percentage points. The year's high was 38.79% on 15 Aug 2022 and its low 8.52% on 15 Dec 2022, averaging 23.30% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.55 days on 29 Jul 2022. Full history: INTERCEPT PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for INTERCEPT PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
28.36% (14 Jan 2022)
End of year
8.74% (30 Dec 2022)
Change
-19.62 pp
High
38.79% (15 Aug 2022)
Low
8.52% (15 Dec 2022)
Average
23.30%
Highest days to cover
15.55 (29 Jul 2022)
SEC filings marked
8

Every report in 2022

INTERCEPT PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202228.36%11.17
31 Jan 202228.20%9.46
15 Feb 202228.27%11.99
28 Feb 202228.83%12.23
15 Mar 202228.63%9.2610-K filed, results (8-K)
31 Mar 202227.73%8.24
14 Apr 202227.70%12.99
29 Apr 202226.90%13.57
13 May 202229.41%3.6310-Q filed, results (8-K)
31 May 202229.99%14.65
15 Jun 202232.86%11.15
30 Jun 202229.94%13.78
15 Jul 202234.70%11.16
29 Jul 202235.77%15.55
15 Aug 202238.79%10.5310-Q filed, results (8-K)
31 Aug 202218.43%4.19
15 Sep 202216.63%7.86
30 Sep 202212.45%3.08
14 Oct 20229.71%4.97
31 Oct 202210.07%6.67
15 Nov 20229.62%4.5610-Q filed, results (8-K)
30 Nov 20228.92%8.65
15 Dec 20228.52%6.23
30 Dec 20228.74%2.97

See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.